New drug could slash opioid use after kidney stone surgery
NCT ID NCT07654296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a new non-opioid painkiller called suzetrigine to standard pain management can reduce opioid use and complications after ureteroscopic surgery for kidney stones. About 100 adults aged 21-80 will receive either suzetrigine or placebo alongside usual care. The goal is to lower pain, opioid consumption, and unplanned hospital visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URETEROSCOPY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Faulkner Hospital
Boston, Massachusetts, 02130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••